GEO DataSets

Analysis of H929 and U266 myeloma cells treated with the natural triterpenoid pristimerin. Multiple myeloma tumors exhibit dysregulated cyclin D expression. Pristimerin identified from a chemical library screen for compounds that induce suppression of transcription from the cyclin D2 promoter.

Organism:

Homo sapiens

Type:

Expression profiling by array, count, 2 agent, 2 cell line sets

Platform:

GPL570

Series:

GSE14011

4 Samples

Download data: CEL

(Submitter supplied) As multiple myeloma tumors universally dysregulate cyclin D genes we conducted high-throughput chemical library screens for compounds that induce suppression of cyclin D2. The top-ranked compound was a natural triterpenoid, pristimerin. We used gene expression microarray studies to identify co-regulated pristimerin-response genes and to deduce the compound’s direct molecular target(s), utilizing pattern-matching algorithms available at the Connectivity Map (Cmap). more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS5279

Platform:

GPL570

4 Samples

Download data: CEL

(Submitter supplied) IT848 is a small molecule inhibiting DNA binding of all five NF-kB subunits. In vitro treatment of lymphoma or multiple myeloma cells with IT848 suppresses NF-kB transcriptional activity, cell growth, and indices apoptosis.

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platform:

GPL11154

12 Samples

Download data: TXT

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:

Homo sapiens

Type:

Expression profiling by array; Genome variation profiling by SNP array

Platforms:

GPL13376 GPL6986 GPL6104

7 Samples

Download data

(Submitter supplied) Chordoma is a rare primary bone malignancy that arises in the skull base, spine and sacrum and originates from remnants of the notochord. These tumors are typically resistant to conventional chemotherapy, and to date there are no FDA-approved agents to treat chordoma. The lack of in vivo models of chordoma has impeded the development of new therapies for this tumor. Primary tumor from a sacral chordoma was xenografted into NOD/SCID/IL-2R γ-null mice. more...

Organism:

Homo sapiens

Type:

Genome variation profiling by SNP array

Platform:

GPL6986

2 Samples

Download data: TXT

(Submitter supplied) Chordoma is a rare primary bone malignancy that arises in the skull base, spine and sacrum and originates from remnants of the notochord. These tumors are typically resistant to conventional chemotherapy, and to date there are no FDA-approved agents to treat chordoma. The lack of in vivo models of chordoma has impeded the development of new therapies for this tumor. Primary tumor from a sacral chordoma was xenografted into NOD/SCID/IL-2R γ-null mice. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platforms:

GPL6104 GPL13376

5 Samples

Download data: TXT